Perspectives in Inflammation

Under the Patronage of H.R.H. The Duchess of Kent

Proceedings of an International Meeting on Future Trends in Inflammation
III

Organized by The European Biological Research Association

Under the auspices of

The Arthritis & Rheumatism Council

The British Pharmacological Society

The British Society of Immunology

The European League Against Rheumatism

The Pathological Society of Great Britain & Ireland

The Royal Society of Medicine

Held at the Grosvenor House Hotel, Park Lane, London, February 14th–18th,
1977

Perspectives in Inflammation

Future Trends and Developments

*The Proceedings of the Third International
Meeting on Future Trends in Inflammation
organized by the European Biological
Research Association and held in London,
February 14th–18th, 1977*

Edited by

D. A. Willoughby

*Professor, Department of Experimental Pathology and Rheumatology,
St. Bartholomew's Hospital, London*

J. P. Giroud

*Professor, Department of Pharmacology, Hôpital Cochin,
Paris*

G. P. Velo

*Professor, Department of Pharmacology, Policlinico Borgo,
Rome*

MTP

Published by
MTP Press Limited
PO Box 55, St. Leonard's House
St. Leonardgate, LANCASTER, England

Copyright © 1977 MTP Press Limited
Softcover reprint of the hardcover 1st edition 1977

First published 1977

No part of this book may be reproduced
in any form without permission from the
publisher except for the quotation of
brief passages for the purpose of review

ISBN 978-94-011-7187-8 ISBN 978-94-011-7185-4 (eBook)
DOI 10.1007/978-94-011-7185-4

Contents

	<i>Page</i>
<i>Preface</i>	xiii
<i>List of Contributors</i>	xv
SECTION I IMMUNOLOGICAL ASPECTS OF INFLAMMATION	
<i>Chairman: J. L. Turk; Co-Chairman: G. A Voisin</i>	
Co-Chairman's Introductory Remarks—Immunostimulation and immunosuppression of what?	3
Guy André Voisin	
1. The rationale of using levamisole in the treatment of rheumatoid arthritis	11
J. Symoens	
2. Immunostimulation, levamisole and rheumatoid arthritis	21
E. C. Huskisson	
3. The effect of cytotoxic drugs on the formation of mononuclear phagocytes	29
R. L. Souhami, J. W. B. Bradfield, N. E. Parker	
4. Rheumatoid factor-immunoglobulin G complex precipitation and neutrophil stimulation: an <i>in vitro</i> model for rheumatoid inflammation	39
R. Turner, H. Mashburn, R. Collins, L. DeChatelet, J. Kaufmann	
Chairman's Summing-up and Future Trends—Immunological aspects of inflammation—the network of interactions	49
J. L. Turk	
<i>General Discussion</i>	56

PERSPECTIVES IN INFLAMMATION

SECTION II CHRONIC INFLAMMATION: CELLULAR EVENTS

Chairman: A. C. Allison; *Co-Chairman:* P. C. Wilkinson

Co-Chairman's Introductory Remarks—Cellular mechanisms in chronic inflammation	63
P. C. Wilkinson	
5. A model for assessing effects of drugs on granulocyte emigration <i>in vivo</i>	69
J. F. Borel, Camille Feurer	
6. A polymorph abnormality in Crohn's disease	75
G. Loewi, A. Segal, P. Tooth	
7. The origin and kinetics of liver macrophages during steady state and inflammation (<i>Abstract</i>)	81
R. van Furth, R. W. Crofton	
8. Lymphocyte-mediated eosinophilia in guinea pigs with delayed hypersensitivity to a chemical	85
W. E. Parrish, E. Luckhurst	
9. A role for L-lymphocytes in chronic inflammation	101
David A. Horwitz	
10. Cartilage degradation by macrophages, fibroblasts and synovial cells in culture. An <i>in vitro</i> model suitable for studies on rheumatoid arthritis	115
G. Vaes, P. Hauser, G. Huybrechts-Godin, C. Peeters-Joris	
11. Adjuvant arthritis: immune responses and effects of Tilorone or interferon in partially suppressing the disease	131
Carl M. Pearson, Yi-Han Chang	
<i>General Discussion</i>	147
Chairman's Summing-up and Future Trends—Cellular reactions in inflammation	150
A. C. Allison	

SECTION III CHRONIC INFLAMMATION: MECHANISMS

Chairman: L. E. Glynn; *Co-Chairman:* I. Ginsburg

Co-Chairman's Introductory Remarks—The role played by leukocyte extracts and inflammatory exudates in the release of lipopolysaccharides from Gram negative bacteria: relation to tissue damage induced during infections	163
I. Ginsberg, Z. Duchan, S. Bergner-Rabinowitz, M. Ferne	

CONTENTS

12. The effect of local elevation of leukocyte cyclic AMP content on lysosomal enzyme release during acute inflammation <i>in vivo</i> D. A. Deporter	169
13. Recent studies on the secretory activity of mononuclear phagocytes with special reference to prostaglandins P. Davies, R. J. Bonney, M. E. Dahlgren, L. Pelus, F. A. Kuehl, Jr., J. L. Humes	179
14. Interactions of macrophages and complement components in the pathogenesis of chronic inflammation H. U. Schorlemmer, J. Ferluga, A. C. Allison	191
15. Matrix vesicles and apatite nodules in arthritic cartilage S. Yousuf Ali	211
16. Crystal induced inflammation and osteoarthritis P. A. Dieppe	225
17. Microanalysis of particulate material involved in inflammation P. A. Dieppe, P. R. Crocker, D. A. Willoughby	233
18. The influence of chemical composition of plasma membranes on the functional activities of macrophages M. Dianzani, F. Feo, R. A. Canuto, R. Garcea, L. Gabriel, M. V. Torrielli	239
<i>Opening to Discussion—Mechanisms in chronic inflammation</i> A. Cats	251
<i>General Discussion</i>	255
Chairman's Summing-up and Future Trends L. E. Glynn	259

SECTION IV GENERAL ASPECTS I

Chairman: J. P. Giroud, Co-Chairman: K. Brune

19. Dual function of E-type prostaglandins in models of chronic inflammation I. L. Bonta, M. J. Parnham, M. J. P. Adolfs, L. van Vliet	265
20. Interactions between prostaglandin E and cyclic nucleotides in chronic inflammatory disease M. J. Parnham, I. L. Bonta, M. J. P. Adolfs	279
21. The time course of the vascular events associated with inflammation due to ultraviolet irradiation of guinea pig ears D. F. Woodward, D. A. A. Owen	289

PERSPECTIVES IN INFLAMMATION

22. Role of macrophages in D-penicillamine-induced stimulation of DNA synthesis in lymph node cells *in vitro*
E. Arrigoni-Martelli, L. Binderup, E. Bramm

295
23. Anti-inflammatory effects of tumour bearing
S. Norman, E. Sorkin

303
24. Role of platelets and of prostaglandin synthetase on hypotensive effects of arachidonic acid and of carrageenan
Bernardo B. Vargaftig, Jean Lefort

317
25. Evidence for a pivotal role of the endoperoxide, PGG₂, in inflammatory processes
F. A. Kuehl, Jr., J. L. Humes, R. W. Egan

331
26. Thiols and prostaglandin biosynthesis
C. Deby, Z. M. Bacq, P. van Caneghem

339
27. Interactions of non-steroidal anti-inflammatory drugs with substance P-like and gastrointestinal hormones-like polypeptides
J. P. Famaey, J. Fontaine, J. Reuse

347
28. Salicylic acid and proquazone: the differences in absorption and biodistribution explain their different profile of side-effects
Alain Schweitzer, Kay Brune

353
29. Degradation of bovine nasal cartilage by a neutral protease from human leukocyte granules
D. Kruze, P. Salgam, K. Fehr, A. Boni

361
30. Inhibition of experimental ocular inflammation by topical application of non-steroidal anti-inflammatory drugs (NSAID)
P. Gautheron, Ph. Conquet, J. C. LeDouarec

371
31. Potentiation of acenocoumarin-induced anticoagulation by a new anti-inflammatory agent in man (*Abstract*)
I. Caruso, M. Fumagalli, F. Montrone, M. B. Donati, R. Latini, G. Bianchetti, L. Carratelli

383
32. *In vitro* methods for assessing anti-inflammatory drug activity (*Abstract*)
A. Tursi, M. P. Loria, G. Specchia, L. Bonomo

387

SECTION V GENERAL ASPECTS II

Chairman: G. P. Velo; *Co-Chairman:* J. Sondergaard

33. Potentiation of antibody formation by proteases *in vitro*
Thomas L. Vischer

393

CONTENTS

~ 34. Triggers of prostaglandin release from macrophages Marcus Glatt, Käthy Wagner, Kay Brune	399
35. Biological, chemical and pharmacological induction of the properdin-mediated pathway of complement activation <i>in vitro</i> T. Di Perri, A. Auteri, F. Laghi Pasini, F. Mattioli	405
36. Immune reactions of lymphocytes eluted from rheumatoid inflammatory tissue T. G. Abrahamsen, S. S. Frøhland, J. B. Natvig, J. Pahle	419
37. Attempts at producing immune complexes <i>in vitro</i> between isolated macroglobulins and purified IgGs Nanna Svartz	427
38. Behaviour of some inflammation parameters in plasma and synovial fluid in some rheumatic diseases (<i>Abstract</i>) R. Numo, V. Pipitone	435
39. Some applications of quantitative two-dimensional immuno-electrophoresis in the study of the systemic acute-phase reaction of the rat R. Scherer, M. Abd-el-Fattah, G. Ruhenstroth-Bauer	437
40. Restoration of the neutrophil chemotactic responsiveness by levamisole treatment in patients with recurrent infections, eczema and hyperimmunoglobulinaemia E R. S. Weening, Liesbeth Stricker, D. Roos, J. L. Molenaar, L. J. Dooren, R. K. B. Schuurman	445
41. Rheumatoid-like joint lesions in rabbits injected intravenously with foreign serum A. R. Poole, R. R. A. Coombs	455
- 42. Anti-inflammatory activity of some bacterial immunostimulants. Relation with macrophage migration P. Lallouette, A. Schwartz	461
43. Inflammatory exudates and mitogenic activity M. Adolphe, J. Fontagne, M. Pelletier, D. Blondelon, P. Lechat, J. P. Giroud	469
44. Secretory activity of epithelioid cells N. Mokhtar, W. G. Spector	481
45. Vascular changes during acute inflammatory responses in rat hindpaws D. A. A. Owen	491

PERSPECTIVES IN INFLAMMATION

SECTION VI PHARMACOLOGICAL ASPECTS: ANIMAL/MAN

Chairman: C. M. Pearson

46. Activators and inhibitors of fibrinolysis in rheumatoid joint inflammation	499
L. B. A. van de Putte, C. Kluft, V. Noordhoek Hegt,
G. Wijngaards, F. Haverkate, A. Cats	
47. Relationships between increased vascular permeability, oedema, hyperalgesia and the effect of non-steroid anti-inflammatory drugs	507
S. H. Ferreira, Maria Teresinha Zanin, Berenice B. Lorenzetti	
48. Two sites of action of steroids on the prostaglandin system	519
G. P. Lewis, P. J. Piper	
49. Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu-Zn superoxide dismutases (orgotein)	527
W. Huber, K. B. Menander-Huber, M. G. P. Saifer,
P. H-C. Dang	
50. Humoral control of monocytopoiesis (<i>Abstract</i>)	545
D. van Waarde, E. Hulsing-Hesselink	

General Discussion

Chairman's Summing-up and Future Trends	550
C. M. Pearson	

SECTION VII PHARMACOLOGICAL ASPECTS: MAN/ANIMAL

Chairman: D. A. Willoughby; *Co-Chairman:* P. Franchimont

Co-Chairman's Opening Remarks	559
P. Franchimont, G. Heynen	
51. Difficulties in the clinical evaluation of new anti-inflammatory drugs	561
G. Katona	
52. Is the mechanism of action during treatment of rheumatoid arthritis with penicillamine and gold thiomalate the same?	575
Egil Jellum, Eimar Munthe	
53. About immunological anomalies in treated and non-treated rheumatoid arthritis: rosette test and immunofluorescence of B-cells	585
H. Roux, P. Mercier, Y. Jeandel, M. T. Gabriel-Brouillet,
G. Serratrice	

CONTENTS

54. Should penicillamine be prescribed for rheumatoid arthritis? W. H. Lyle	591
55. Long-term evaluation of intermittent levamisole treatment in rheumatoid arthritis E. M. Veys, H. Mielants	599
<i>General Discussion</i>	610
Closing Remarks D. A. Willoughby	616
POSTER SESSIONS	619

Preface

This report on Future Trends in Inflammation III is the record of what is now firmly established as a series of multidisciplinary meetings organized by the European Biological Research Association. The aim of these meetings is to provide a forum for free exchange of information between basic scientists of many disciplines and clinicians to provide better understanding of problems of common interest. The next major meeting will be held in 1980.*

The European Biological Research Association promotes scientific and clinical collaboration among the member countries of the EEC. It encourages exchange of information between scientists and clinicians from centres all over the world. In addition to the major international meetings small workshops are organized on specific problems of common interest.

Once again the Editors have attempted to capture the spirit of the meeting by publishing 'verbatim' the discussion. It can be seen that the discussions were exciting and formed an important part of the meeting.

It is possible that inaccuracies have crept into the discussions; if so we apologize. It was decided that the proceedings of such a meeting had maximum value with rapid publication.

We would like to thank the participants for the enthusiasm and goodwill which persisted throughout the meeting both scientifically and socially.

Above all we wish to thank H.R.H. The Duchess of Kent for acting as Patron of this meeting.

D. A. Willoughby
J. P. Giroud
G. P. Velo

* For further information regarding the 1980 meeting please contact Professor D. A. Willoughby of Department of Experimental Pathology, St. Bartholomew's Hospital, London, EC1A 7BE, England.

List of Contributors

JAN AASETH

Institute of Clinical Biochemistry,
Rikshospitalet, Oslo, 1, Norway

M. ABD-EL-FATTAH

Department of Biochemistry, Faculty of
Science, Ain Sams University, Cairo,
Egypt

T. G. ABRAHAMSEN

Institute of Immunology and
Rheumatology, Rikshospitalet, Oslo 1,
Norway

M. J. P. ADOLFS

Department of Pharmacology, Faculty of
Medicine, Erasmus University,
Rotterdam, The Netherlands

M. ADOLPHE

Laboratory of Cellular Pharmacology,
College for Advanced Studies,
Centre de Recherches de l'Association
Claude Bernard, F-75006 Paris, France

S. YOUSUF ALI

Experimental Pathology Unit, Institute of
Orthopaedics, University of London,
Royal National Orthopaedic Hospital,
Stanmore, Middlesex, HA7 4LP

A. C. ALLISON

MRC Clinical Research Centre,
Harrow, Middlesex, HA1 3UJ

E. ARRIGONI-MARTELLI

Department of Pharmacology,
Leo Pharmaceutical Products,
DK-2750 Ballerup, Denmark

A. AUTERI

Institute of Medical Semeiotics, School of
Medicine, University of Sienna, Italy

Z. M. BACQ

Applied Biochemistry Laboratory,

University of Liege, B-4020 Liege,
Belgium

S. BERGNER-RABINOWITZ

The Department of Oral Biology,
Hadassah School of Medicine,
The Hebrew University, Jerusalem,
Israel

G. BIANCHETTI

Rheumatology Service, L. Sacco Hospital,
Milan, Italy

L. BINDERUP

Department of Pharmacology,
Leo Pharmaceutical Products,
DK-2750 Ballerup, Denmark

D. BLANDELON

Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre de
Recherches de l'Association Claude
Bernard, F-75006 Paris, France

A. BÖNI

Department of Rheumatology, University
of Zurich, Cantonal Hospital, CH-8091
Zurich, Switzerland

R. J. BONNEY

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

L. BONOMO

Institute of Clinical Medicine II,
University of Bari, Policlinico, I-70124,
Bari, Italy

I. L. BONTA

Department of Pharmacology, Faculty
of Medicine, Erasmus University,
Rotterdam, The Netherlands

J. F. BOREL

Biological and Medical Research

PERSPECTIVES IN INFLAMMATION

Division, Sandoz Ltd., CH-4002 Basel,
Switzerland

J. W. D. BRADFIELD

Department of Experimental Pathology,
St. Mary's Hospital Medical School,
London, W.2

E. BRAMM

Department of Pathology, Leo
Pharmaceutical Products, DK-2750
Ballerup, Denmark

K. BRUNE

University of Basel, CH-4056 Basel,
Switzerland

P. van CANEGHEM

Applied Biochemistry Laboratory,
University of Liege, B-4020 Liege,
Belgium

R. A. CANUTO

Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

L. CARRATELLI

Merck Sharp and Dohme (Italia) S.p.a.,
I-00191 Rome, Italy

L. CARUSO

Rheumatology Service, L. Sacco
Hospital, Milan, Italy

A. CATS

Department of Rheumatology, University
Hospital, Leiden, The Netherlands

Y.-H. CHANG

Division of Rheumatology, Department
of Medicine, UCLA School of Medicine,
Los Angeles, California 90024, USA

L. DeCHATELET

Department of Biochemistry, The
Bowman Gray School of Medicine,
Wake Forest University, Winston-Salem,
North Carolina 27103, USA

R. COLLINS

Department of Biochemistry, The Bowman
Gray School of Medicine, Wake Forest
University, Winston-Salem, North
Carolina 27103, USA

Ph. CONQUET

MSD-Chibret Research Institute, F-63018
Clermont-Ferrand, France

R. R. A. COOMBS

Division of Immunology, Department of
Pathology, University of Cambridge

P. R. CROCKER

Department of Rheumatology and
Experimental Pathology, St.
Bartholomew's Hospital, London, E.C.1

R. W. CROFTON

Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

M. E. DAHLGREN

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

P. H.-C. DANG

Diagnostic Data Inc., Mountain View,
California 94043, USA

P. DAVIES

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

C. DEBY

Applied Biochemistry Laboratory,
University of Liege, B-4020 Liege,
Belgium

D. A. DEPORTER

Faculty of Dentistry, University of
Toronto, Toronto, Canada

M. DIANZANI

Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

P. A. DIEPPE

Department of Rheumatology and
Experimental Pathology, St.
Bartholomew's Hospital, London,
E.C.1

M. B. DONATI

Rheumatology Service, L. Sacco Hospital,
Milan, Italy

L. J. DOOREN

Department of Paediatrics, University
Hospital, Leiden, The Netherlands

J. C. LeDOUAREC

MSD-Chibret Research Institute,
F-63018
Clermont-Ferrand, France

LIST OF CONTRIBUTORS

Z. DUCHAN

The Department of Oral Biology,
Hadassah School of Medicine, The
Hebrew University, Jerusalem, Israel

R. W. EGAN

Merck Institute for Therapeutic
Research, Rahway, New Jersey 07065,
USA

J. P. FAMAHEY

Laboratory of Pharmacology,
Rheumatology Unit, School of Medicine,
University of Brussels, B-1000 Brussels,
Belgium

K. FEHR

Department of Rheumatology, University
of Zurich, Cantonal Hospital, CH-8091
Zurich, Switzerland

F. FEO

Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

J. FERLUGA

Institute of Medical Microbiology,
Johannes Gutenberg University, D-6500
Mainz, West Germany

M. FERNE

The Department of Oral Biology,
Hadassah Medical School, The Hebrew
University, Jerusalem, Israel

S. H. FERREIRA

Department of Pharmacology, Faculty
of Medicine, University of Sao Paulo,
Sao Paulo, Brazil

CAMILLE FEURER

Biological and Medical Research Division,
Sandoz Ltd., CH-4002 Basel,
Switzerland

J. FONTAGNE

Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre de
Recherches de l'Association Claude
Bernard, F-75006 Paris, France

J. FONTAINE

Laboratory of Pharmacology,
Rheumatology Unit, School of Medicine,
University of Brussels, B-1000 Brussels,
Belgium

P. FRANCHIMONT

Radioimmunology Laboratory, University
of Liege, B-4000 Liege, Belgium

S. S. FRØHLAND

Institute of Immunology and
Rheumatology, Rikshospitalet, Oslo 1,
Norway

M. FUMGALLI

Rheumatology Service, L. Sacco Hospital,
Milan, Italy

R. van FURTH

Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

L. GABRIEL

Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

M. T. GABRIEL-BROUILLET

Rheumatology Clinic, C.H.U. Tirrone,
Marseilles, France

R. GARCEA

Institute of General Pathology, University
of Turin, I-10125 Turin, Italy

P. GAUTHERON

MSD-Chibret Research Institute, F-63018
Clermont-Ferrand, France

I. GINSBURG

The Department of Oral Biology,
Hadassah School of Medicine, The
Hebrew University, Jerusalem, Israel

J. P. GIROUD

Department of Pharmacology, Hospital
Cochin, Paris 14, France

M. GLATT

Department of Pharmacology, University
of Basel, CH-4056 Basel, Switzerland

L. E. GLYNN

Kennedy Institute of Rheumatology,
Hammersmith, London W6 7DW

P. HAUSER

Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium

PERSPECTIVES IN INFLAMMATION

F. HAVERKATE

Gaubius Institute, Health Research
Organization TNO, Leiden, The
Netherlands

G. HEYNEN

Radioimmunology Laboratory,
University of Liege, B-4000 Liege,
Belgium

D. A. HOROWITZ

Division of Rheumatology, Department
of Internal Medicine, University of
Virginia School of Medicine,
Charlottesville, Virginia 22901, USA

W. HUBER

Diagnostic Data Inc., Mountain View,
California 94043, USA

E. HULSING-HESELINK

Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

J. L. HUMES

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

E. C. HUSKISSON

St. Bartholomew's Hospital, London

G. HUYBRECHT-GODIN

Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium

Y. JEANDEL

Rheumatology Clinic, C.H.U. Tիրոնե,
Marseilles, France

E. JELLUM

Institute of Clinical Biochemistry,
Rikshospitalet, Oslo 1, Norway

G. KATONA

Rheumatology Service, General Hospital,
Mexico City, Mexico, D. F.

J. KAUFMANN

Department of Biochemistry, The Bowman
Gray School of Medicine, Wake Forest
University, Winston-Salem, North
Carolina 27103, USA

C. KLIFT

Department of Rheumatology, University
Hospital, Leiden, The Netherlands

D. KRUIZE

Department of Rheumatology, University
of Zurich, Cantonal Hospital, CH-8091
Zurich, Switzerland

F. A. KUEHL, Jr.

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

P. LALLOUETTE

41, rue Camille Pelletan, F-92305
Levallois-Perret, France

R. LATINI

Rheumatology Service, L. Sacco Hospital,
Milan, Italy

P. LECHAT

Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre
de Recherches de l'Association Claude
Bernard, F-75006 Paris, France

J. LEFORT

Centre de Recherches Merrell International
F-67084 Strasbourg, France

G. P. LEWIS

Department of Pharmacology, Royal
College of Surgeons of England,
London, WC2A 3PN

G. LOEWI

MRC Clinical Research Centre, Harrow,
Middlesex, HA1 3UJ

BERENICE B. LORENZETTI

Department of Pharmacology, Faculty
of Medicine, University of Sao Paulo,
Sao Paulo, Brazil

M. P. LORIA

Institute of Clinical Medicine II,
University of Bari, Policlinico, I-70124,
Bari, Italy

E. LUCKHURST

Lister Institute of Preventive Medicine,
Elstree, Herts

W. H. LYLE

Dista Products Limited, Speke, Liverpool,
L24 9LN

H. MASHBURN

Department of Biochemistry, The Bowman
Gray School of Medicine, Wake Forest
University, Winston-Salem, North
Carolina 27103, USA

LIST OF CONTRIBUTORS

K. B. MENANDER-HUBER

Diagnostic Data Inc., Mountain View,
California 94043, USA

P. MERCIER

Transfusion Centre, Marseilles, France

H. MIELANTS

Section of Rheumatology, University
Hospital, B-9000 Ghent, Belgium

N. MOKHTAR

Department of Pathology, St.
Bartholomew's Hospital Medical College,
London

J. L. MOLENAAR

Central Laboratory of the Netherlands'
Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands

F. MONTRONE

Rheumatology Service, L. Sacco Hospital,
Milan, Italy

E. MUNTHE

Oslo Rheumatism Hospital, Oslo 1,
Norway

J. B. NATVIG

Oslo Rheumatism Hospital, Oslo 1,
Norway

V. NOORDHOEK HEGT

Gabius Institute, Health Research
Organization TNO, Leiden, The
Netherlands

S. NORMANN

Department of Pathology, College of
Medicine, University of Florida,
Gainesville, Florida 32610, USA

R. NUMO

Rheumatology Service, University of
Bari, Policlinico, I-70124 Bari, Italy

D. A. A. OWEN

Department of Pharmacology, The
Research Institute, Smith Kline and
French Laboratories Ltd., Welwyn
Garden City, Herts

J. PAHLE

Oslo Rheumatism Hospital, Oslo 1,
Norway

W. E. PARISH

Unilever Research, Colworth House,
Sharnbrook, Bedford

N. E. PARKER

University College Hospital Medical
School, London

M. J. PARNHAM

Department of Pharmacology, Faculty
of Medicine, Erasmus University,
Rotterdam, The Netherlands

F. LAGHI PASINI

Institute of Medical Semeiotics, School
of Medicine, University of Sienna,
Sienna, Italy

C. M. PEARSON

Division of Rheumatology, Department
of Medicine, UCLA School of Medicine,
Los Angeles, California, USA

C. PEETERS-JORIS

Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium

M. PELLETIER

Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre de
Recherches de l'Association Claude
Bernard, F-75006 Paris, France

L. PELUS

Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

T. Di PERRI

Institute of Medical Semeiotics, School
of Medicine, University of Sienna,
Sienna, Italy

P. J. PIPER

Department of Pharmacology, Royal
College of Surgeons of England,
London, WC2A 3PN

V. PIPITONE

Rheumatology Service, University of
Bari, Policlinico, I-70124 Bari, Italy

A. R. POOLE

Joint Diseases Laboratory,
Shriners Hospital for Crippled Children,
Montreal, Quebec, H3G 1A6, Canada

L. B. A. van de PUTTE

Department of Rheumatology, University
Hospital, Leiden, The Netherlands

LIST OF CONTRIBUTORS

B. VARGAFTIG

Centre de Recherche Merrell International,
F-67084 Strasbourg, France

G. VAES

Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium

G. P. VELO

Department of Pharmacology,
Policlinico Borgo Roma, I-37100 Verona,
Italy

E. M. VEYS

Rheumatology Section, University
Hospital, B-9000 Ghent, Belgium

T. L. VISCHER

Department of Rheumatology,
University of Geneva, Hôpital Cantonal
CH-1211 Geneva, Switzerland

L. van VLIET

Department of Pharmacology, Faculty
of Medicine, Erasmus University,
Rotterdam, The Netherlands

G. A. VOISIN

Centre of Immuno-Pathology and
Experimental Immunology,
l'Association Claude Bernard, Hôpital
Saint-Antoine, F-75012 Paris, France

D. van WAARDE

Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

KÄTHY WAGNER

Department of Pharmacology, University
of Basel, CH-4056 Basel, Switzerland

R. S. WEENING

Central Laboratory of the Netherlands'
Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands

G. WIJNGAARDS

Gaubius Institute, Health Research
Organization TNO, Leiden, The
Netherlands

P. C. WILKINSON

Bacteriology and Immunology
Department, University of Glasgow,
Western Infirmary, Glasgow, G11 6NT

D. A. WILLOUGHBY

Department of Rheumatology and
Experimental Pathology, St.
Bartholomew's Hospital, London,
E.C.1

D. F. WOODWARD

Department of Pathology, The Research
Institute, Smith Kline and French
Laboratories Limited, Welwyn Garden
City, Herts

MARIA TERESINHA ZANIN

Department of Pharmacology, Faculty
of Medicine, University of Sao Paulo,
Sao Paulo, Brazil